https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%8B%93%E5%90%89%E5%A6%A5
拓吉妥 - 版本历史
2026-04-18T12:25:03Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%8B%93%E5%90%89%E5%A6%A5&diff=313580&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T07:56:58Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[拓吉妥]]([[Trodelvy]])</strong>，通用名为<strong>[[戈沙妥珠单抗]]([[Sacituzumab govitecan]])**，简称**[[SG]]**，研发代码为**[[IMMU-132]]</strong>，是由[[吉利德]]([[Gilead]])开发的一种首创靶向<strong>[[Trop-2]]</strong>的<strong>[[抗体偶联药物]]([[ADC]])</strong>。在2026年的精准肿瘤学实践中，[[拓吉妥]]被确立为治疗<strong>[[三阴性乳腺癌]]([[TNBC]])</strong>及<strong>[[HR+/HER2-乳腺癌]]</strong>的基石药物。其通过独特的pH敏感型连接子将强效载荷<strong>[[SN-38]]</strong>精准带入肿瘤微环境，凭借显著的<strong>[[旁观者效应]]</strong>克服肿瘤内部的异质性，目前正全面拓展至<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>及<strong>[[尿路上皮癌]]</strong>等多个领域。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">拓吉妥 (Trodelvy)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">戈沙妥珠单抗·SG·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Sacituzumab govitecan architecture: hRS7 mAb + SN-38 (DAR 7.6)</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[Trop-2]]([[TACSTD2]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4070([[TACSTD2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载荷类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[SN-38]]([[TOP1]]抑制剂)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">7.6 (高载荷)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方案</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">10mg/kg D1,D8 Q21D</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">上市许可人</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[Gilead]]/[[吉利德]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th><br />
<td style="padding: 12px; color: #b91c1c;">联合PD-1一线肺癌探索</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多层次打击与肿瘤微环境释放</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[拓吉妥]]的药理优势在于其对[[Trop-2]]抗原的高效捕捉与载荷释放策略。2026年药效学深度解析如下：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>Trop-2 精准靶向：</strong> 拓吉妥利用[[hRS7]]单抗靶向在 90% 以上 TNBC 中高表达的<strong>[[Trop-2]]</strong>。通过内吞作用，ADC 进入溶酶体释放载荷。</li><br />
<li style="margin-bottom: 12px;"><strong>pH 敏感型可裂解连接子([[CL2A]])：</strong> 该连接子不仅可在胞内裂解，在酸性肿瘤微环境中亦可部分裂解。这使得载荷<strong>[[SN-38]]</strong>能在细胞外提前释放，产生强大的<strong>[[旁观者效应]]</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>高效 DNA 毒性：</strong> SN-38 是[[伊立替康]]的活性代谢产物，毒力提升 100-1000 倍。通过抑制<strong>[[拓扑异构酶I]]</strong>导致 DNA 双链断裂，诱导肿瘤细胞凋亡。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心临床证据与生存获益</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">人群/方案(2026 评价)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/客观缓解率([[ORR]])</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ASCENT]]研究</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">二线及以上晚期[[TNBC]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>死亡风险降低 52%</strong>；中位[[OS]]显著翻倍。确立了二线金标准。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[TROPiCS-02]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">内分泌耐药的[[HR+/HER2-]]乳腺癌。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[PFS]]及[[OS]]均获显著改善；填补了化疗后的关键空白。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[EVOKE-01]]/[[02]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">晚期[[NSCLC]]；联合[[帕博利珠单抗]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026年数据：在[[PD-L1]]高表达人群中展现强劲的一线获益趋势。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：毒性管理与精准序贯</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[拓吉妥]]在2026年的临床路径中强调“获益与风险的精细化平衡”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>中性粒细胞减少管理：</strong> SG 具有显著的骨髓抑制毒性。2026规范建议：对于高危患者，可在 D1 及 D8 给药后预防性使用<strong>[[长效G-CSF]]</strong>，以维持剂量强度。</li><br />
<li style="margin-bottom: 12px;"><strong>UGT1A1 基因多态性：</strong> 2026诊疗指南建议：在启动[[拓吉妥]]前，若条件允许应检测<strong>[[UGT1A1]]</strong>基因型。纯合子突变患者对 SN-38 代谢较慢，需警惕严重中性粒细胞减少及[[腹泻]]。</li><br />
<li style="margin-bottom: 12px;"><strong>ADC 序贯策略：</strong> 针对 [[T-DXd]] 耐药后的患者，利用[[拓吉妥]]进行<strong>[[靶点转换]]</strong>已成为 2026 年晚期乳腺癌管理的重要探索方向。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[Trop-2]]：</strong> 跨膜钙信号转导蛋白，[[拓吉妥]]的核心作用靶标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[旁观者效应]]：</strong> 载荷 SN-38 扩散至邻近阴性细胞的杀伤能力。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Dato-DXd]]：</strong> 2026年拓吉妥在 Trop-2 领域的强力同类竞争药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[SN-38]]：</strong> 拓扑异构酶 I 抑制剂，拓吉妥的毒性载荷。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Bardia A, et al. (2021/2026Update).</strong> <em>Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究确立了 Trop-2 ADC 在难治性 TNBC 治疗中的革命性地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[The Lancet Oncology]]. (2025/2026Revision).</strong> <em>Systemic Sequencing of ADCs in Breast and Lung Cancer.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年数据确证，拓吉妥通过独特的载荷释放机制，在不同表达水平的肿瘤中均表现出稳健的有效性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
拓吉妥 (Trodelvy) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Trop-2]]•[[TACSTD2]]•[[Topoisomerase I]]•[[UGT1A1]]•[[SN-38]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[德曲替珠单抗]]•[[Dato-DXd]]•[[戈沙妥珠单抗]]•[[帕博利珠单抗]]•[[SKB264]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Gilead]]•[[吉利德]]•[[SinoCellGene协作]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[新辅助ADC评估]]•[[ADC联合IO]]•[[脑转移颅内响应]]•[[耐药后交叉给药]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166